235 related articles for article (PubMed ID: 17085682)
1. A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer.
Cybulski C; Wokołorczyk D; Huzarski T; Byrski T; Gronwald J; Górski B; Debniak T; Masojć B; Jakubowska A; Gliniewicz B; Sikorski A; Stawicka M; Godlewski D; Kwias Z; Antczak A; Krajka K; Lauer W; Sosnowski M; Sikorska-Radek P; Bar K; Klijer R; Zdrojowy R; Małkiewicz B; Borkowski A; Borkowski T; Szwiec M; Narod SA; Lubiński J
J Med Genet; 2006 Nov; 43(11):863-6. PubMed ID: 17085682
[TBL] [Abstract][Full Text] [Related]
2. A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland.
Cybulski C; Wokołorczyk D; Huzarski T; Byrski T; Gronwald J; Górski B; Debniak T; Masojć B; Jakubowska A; van de Wetering T; Narod SA; Lubiński J
Breast Cancer Res Treat; 2007 Mar; 102(1):119-22. PubMed ID: 16897426
[TBL] [Abstract][Full Text] [Related]
3. Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations?
Cybulski C; Wokołorczyk D; Kładny J; Kurzawski G; Suchy J; Grabowska E; Gronwald J; Huzarski T; Byrski T; Górski B; D Ecedil Bniak T; Narod SA; Lubiński J
Eur J Hum Genet; 2007 Feb; 15(2):237-41. PubMed ID: 17106448
[TBL] [Abstract][Full Text] [Related]
4. A novel founder CHEK2 mutation is associated with increased prostate cancer risk.
Cybulski C; Huzarski T; Górski B; Masojć B; Mierzejewski M; Debniak T; Gliniewicz B; Matyjasik J; Złowocka E; Kurzawski G; Sikorski A; Posmyk M; Szwiec M; Czajka R; Narod SA; Lubiński J
Cancer Res; 2004 Apr; 64(8):2677-9. PubMed ID: 15087378
[TBL] [Abstract][Full Text] [Related]
5. CHEK2*1100delC is not an important high-risk gene in families with hereditary prostate cancer in southern Sweden.
Wagenius M; Borg A; Johansson L; Giwercman A; Bratt O
Scand J Urol Nephrol; 2006; 40(1):23-5. PubMed ID: 16452051
[TBL] [Abstract][Full Text] [Related]
6. BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases.
Falchetti M; Lupi R; Rizzolo P; Ceccarelli K; Zanna I; Calò V; Tommasi S; Masala G; Paradiso A; Gulino A; Giannini G; Russo A; Palli D; Ottini L
Breast Cancer Res Treat; 2008 Jul; 110(1):161-7. PubMed ID: 17661168
[TBL] [Abstract][Full Text] [Related]
7. CHEK2 1100delC, IVS2+1G>A and I157T mutations are not present in colorectal cancer cases from Turkish population.
Bayram S; Topaktaş M; Akkız H; Bekar A; Akgöllü E
Cancer Epidemiol; 2012 Oct; 36(5):453-7. PubMed ID: 22521562
[TBL] [Abstract][Full Text] [Related]
8. Increased risk of breast cancer associated with CHEK2*1100delC.
Weischer M; Bojesen SE; Tybjaerg-Hansen A; Axelsson CK; Nordestgaard BG
J Clin Oncol; 2007 Jan; 25(1):57-63. PubMed ID: 16880452
[TBL] [Abstract][Full Text] [Related]
9. A common nonsense mutation of the BLM gene and prostate cancer risk and survival.
Antczak A; Kluźniak W; Wokołorczyk D; Kashyap A; Jakubowska A; Gronwald J; Huzarski T; Byrski T; Dębniak T; Masojć B; Górski B; Gromowski T; Nagorna A; Gołąb A; Sikorski A; Słojewski M; Gliniewicz B; Borkowski T; Borkowski A; Przybyła J; Sosnowski M; Małkiewicz B; Zdrojowy R; Sikorska-Radek P; Matych J; Wilkosz J; Różański W; Kiś J; Bar K; Domagała P; Stawicka M; Milecki P; Akbari MR; Narod SA; Lubiński J; Cybulski C; ; ; Bryniarski P; Paradysz A; Jersak K; Niemirowicz J; Słupski P; Jarzemski P; Skrzypczyk M; Dobruch J; Domagała W; Chosia M; van de Wetering T; Serrano-Fernández P; Puszyński M; Soczawa M; Switała J; Archimowicz S; Kordowski M; Zyczkowski M; Borówka A; Bagińska J; Krajka K; Szwiec M; Haus O; Janiszewska H; Stembalska A; Sąsiadek MM
Gene; 2013 Dec; 532(2):173-6. PubMed ID: 24096176
[TBL] [Abstract][Full Text] [Related]
10. Homozygosity for a CHEK2*1100delC mutation identified in familial colorectal cancer does not lead to a severe clinical phenotype.
van Puijenbroek M; van Asperen CJ; van Mil A; Devilee P; van Wezel T; Morreau H
J Pathol; 2005 Jun; 206(2):198-204. PubMed ID: 15818573
[TBL] [Abstract][Full Text] [Related]
11. Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.
Laitman Y; Kaufman B; Lahad EL; Papa MZ; Friedman E
Isr Med Assoc J; 2007 Nov; 9(11):791-6. PubMed ID: 18085035
[TBL] [Abstract][Full Text] [Related]
12. A simple method of investigating mutations in CHEK2 by DHPLC: a study of the German populations of Saxony, Saxony-Anhalt, and Thuringia.
Scharrer U; Skrzypczak-Zielinska M; Wituszynska W; Mierzejewski M; Krause K; Cybulski C; Froster UG
Cancer Genet Cytogenet; 2010 May; 199(1):48-52. PubMed ID: 20417869
[TBL] [Abstract][Full Text] [Related]
13. CHEK2 gene alterations in the forkhead-associated domain, 1100delC and del5395 do not modify the risk of sporadic pancreatic cancer.
Mohelnikova-Duchonova B; Havranek O; Hlavata I; Foretova L; Kleibl Z; Pohlreich P; Soucek P
Cancer Epidemiol; 2010 Oct; 34(5):656-8. PubMed ID: 20643596
[TBL] [Abstract][Full Text] [Related]
14. Low frequency of the CHEK2*1100delC mutation among breast cancer probands from three regions of Poland.
Kwiatkowska E; Skasko E; Niwinska A; Wojciechowska-Lacka A; Rachtan J; Molong L; Nowakowska D; Konopka B; Janiec-Jankowska A; Paszko Z; Steffen J
Neoplasma; 2006; 53(4):305-8. PubMed ID: 16830057
[TBL] [Abstract][Full Text] [Related]
15. Germline mutations in the CHEK2 kinase gene are associated with an increased risk of bladder cancer.
Złowocka E; Cybulski C; Górski B; Debniak T; Słojewski M; Wokołorczyk D; Serrano-Fernández P; Matyjasik J; van de Wetering T; Sikorski A; Scott RJ; Lubiński J
Int J Cancer; 2008 Feb; 122(3):583-6. PubMed ID: 17918154
[TBL] [Abstract][Full Text] [Related]
16. Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer.
Domagala P; Wokolorczyk D; Cybulski C; Huzarski T; Lubinski J; Domagala W
Breast Cancer Res Treat; 2012 Apr; 132(3):937-45. PubMed ID: 21701879
[TBL] [Abstract][Full Text] [Related]
17. CHEK2 1100delC and male breast cancer in the Netherlands.
Wasielewski M; den Bakker MA; van den Ouweland A; Meijer-van Gelder ME; Portengen H; Klijn JG; Meijers-Heijboer H; Foekens JA; Schutte M
Breast Cancer Res Treat; 2009 Jul; 116(2):397-400. PubMed ID: 18759107
[TBL] [Abstract][Full Text] [Related]
18. Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations.
Cybulski C; Górski B; Huzarski T; Byrski T; Gronwald J; Debniak T; Wokolorczyk D; Jakubowska A; Serrano-Fernández P; Dork T; Narod SA; Lubinski J
J Med Genet; 2009 Feb; 46(2):132-5. PubMed ID: 18930998
[TBL] [Abstract][Full Text] [Related]
19. CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women.
Adank MA; Jonker MA; Kluijt I; van Mil SE; Oldenburg RA; Mooi WJ; Hogervorst FB; van den Ouweland AM; Gille JJ; Schmidt MK; van der Vaart AW; Meijers-Heijboer H; Waisfisz Q
J Med Genet; 2011 Dec; 48(12):860-3. PubMed ID: 22058428
[TBL] [Abstract][Full Text] [Related]
20. The CHEK2 c.1100delC germline mutation rarely contributes to breast cancer development in the Czech Republic.
Kleibl Z; Novotny J; Bezdickova D; Malik R; Kleiblova P; Foretova L; Petruzelka L; Ilencikova D; Cinek P; Pohlreich P
Breast Cancer Res Treat; 2005 Mar; 90(2):165-7. PubMed ID: 15803363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]